secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001641172-25-000209
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem reports 2024 net sales up 6% to $19.4M; operating loss improved 57% YoY
------------------------------------------------------------------------------

- 2024 net sales $19.4M (+6% YoY); operating loss $7.7M vs $17.8M in 2023, improvement of 57%.
- Q4 2024 net sales $7.1M vs $4.8M Q4 2023; Q4 operating loss $1.0M vs $3.4M.
- Sales & marketing expense fell to 47% of net sales for FY2024, down from 64% in 2023.
- Merger with Aditxt: $1.5M funding due by Apr 7, 2025; stockholder meeting by Sep 26, 2025; close by Sep 30, 2025.
- Raised $2.7M from Aditxt in Oct 2024; used to pay FDA obligations; year-end restricted cash $0.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000164117225000209/0001641172-25-000209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000164117225000209/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-000209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer